De Novo Ventures, of Menlo Park, Calif., appointed Cathy Minshall chief financial officer.

Durect Corp., of Cupertino, Calif., appointed Peter Langecker chief medical officer.

Dusa Pharmaceuticals Inc., of Wilmington, Mass., hired William O'Dell as executive vice president, sales and marketing.

Exaeris Inc., of Exton, Pa., appointed Bruce Simpson and William Storms to its board.

Fovea Pharmaceuticals SA, of Paris, appointed Barrett Katz executive vice president and chief medical officer.

Genentech Inc., of South San Francisco, appointed William Anderson vice president, sales and marketing, immunology; Scott Carmer vice president, sales and marketing, Rituxan immunology; Pamela Klein vice president, clinical oncology, hematology and HER family; and Mary Sliwkowski vice president, regulatory affairs, chemistry manufacturing and controls.

Genesis Bioventures Inc., of New York, appointed Douglas Lane interim CEO, president and chairman.

Genomic Health Inc., of Redwood City, Calif., appointed Woodrow Myers to its board.

GPC Biotech AG, of Martinsried, Germany, appointed Martine George senior vice president, clinical development; Ramona Lloyd vice president, worldwide regulatory affairs and quality compliance; and Margaret Ference vice president, U.S. sales.

ImaRx Therapeutics Inc., of Tucson, Ariz., appointed Richard Love and Philip Ranker to its board.

Invitrogen Corp., of Carlsbad, Calif., appointed Mahendra Rao vice president, research, stem cells and regenerative medicine.

Ista Pharmaceuticals Inc., of Irvine, Calif., appointed Andrew Perlman to its board.

Javelin Pharmaceuticals Inc., of Cambridge, Mass., appointed Stephen Tulipano chief financial officer.

Migenix Inc., of Vancouver, British Columbia, appointed AnnKatrin Petersen vice president of clinical development.

Molecular Insight Pharmaceuticals Inc., of Cambridge, Mass., appointed David Stack to its board.

Momenta Pharmaceuticals Inc., of Cambridge, Mass., appointed Paul Goldenheim to its board.

Neuromed Pharmaceuticals, of Vancouver, British Columbia, appointed Stephen Arneric vice president of research and preclinical development.

New River Pharmaceuticals Inc., of Radford, Va., appointed John Thottathil chief scientific officer.

Novavax Inc., of Malvern, Pa., appointed James Tananbaum to its board.

Novocell Inc., of Irvine, Calif., appointed Alan Lewis president and CEO.

NPS Pharmaceuticals, of Salt Lake City, appointed Juergen Lasowski senior vice president of corporate development.

Ocera Therapeutics Inc., of San Diego, appointed Xavier Frapaise chief medical officer.

Ortec International Inc., of New York, formed a stem cell and regenerative medicine scientific advisory board to be led by Daniel Marshak as chairman.

Oxxon Therapeutics, of Oxford, UK, appointed Craig Smith chairman and John Berriman executive deputy chairman.

PDL BioPharma Inc., of Fremont, Calif., appointed Bradford Goodwin to its board.

Pharsight Corp., of Mountain View, Calif., appointed Will Frederick senior vice president and chief financial officer.

Phytomedics Inc., of Jamesburg, N.J., appointed Steven Burrill to its board.

PPD Inc., of Wilmington, N.C., appointed Thomas Rosanske executive director of product development analytical services for its cGMP laboratory.

Protedyne Corp., of Windsor, Conn., appointed Roch Kelly chief operating officer.

PTC Therapeutics Inc., of South Plainfield, N.J., promoted Claudia Hirawat to senior vice president of corporate development.

RBC Capital Markets, of New York, appointed Simon Gill co-head of the U.S. investment banking health care group. Kevin Davies also will serve as co-head.

Replikun Biotech, of Brisbane, Australia, appointed Nick Samaras chairman.